These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21736392)

  • 1. Value-based pricing: incentive for innovation or zero net benefit?
    Hughes DA
    Pharmacoeconomics; 2011 Sep; 29(9):731-5. PubMed ID: 21736392
    [No Abstract]   [Full Text] [Related]  

  • 2. Value-based pricing of drugs in the UK.
    Webb DJ; Walker A
    Lancet; 2007 Apr; 369(9571):1415-1416. PubMed ID: 17467498
    [No Abstract]   [Full Text] [Related]  

  • 3. The economic value of companion diagnostics and stratified medicines.
    Blair ED; Stratton EK; Kaufmann M
    Expert Rev Mol Diagn; 2012 Nov; 12(8):791-4. PubMed ID: 23249194
    [No Abstract]   [Full Text] [Related]  

  • 4. Pricing schemes for new drugs: a welfare analysis.
    Levaggi R
    Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pandora's Prescription: The Pharmaceutical Pricing
    Pederson T
    FASEB J; 2017 Nov; 31(11):4661-4662. PubMed ID: 29093000
    [No Abstract]   [Full Text] [Related]  

  • 7. Market watch: pricing strategies for emerging markets.
    Lineberry N; Snyder E; Gunda S
    Nat Rev Drug Discov; 2011 Aug; 10(8):567. PubMed ID: 21804586
    [No Abstract]   [Full Text] [Related]  

  • 8. Excluding NICE from early stages of value based pricing scheme was "big win for pharma," conference is told.
    Limb M
    BMJ; 2013 Nov; 347():f6906. PubMed ID: 24246840
    [No Abstract]   [Full Text] [Related]  

  • 9. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
    Ogbighele E
    IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicines pricing singled out.
    Buchanan E
    S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
    [No Abstract]   [Full Text] [Related]  

  • 12. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
    Towse A
    Br J Clin Pharmacol; 2010 Sep; 70(3):360-6. PubMed ID: 20716236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Priced out of the UK market.
    Moran N
    Nat Biotechnol; 2008 Feb; 26(2):151-4. PubMed ID: 18259163
    [No Abstract]   [Full Text] [Related]  

  • 14. New prescription for the Spanish drug sector: fighting against public deficit without wasting ammunition.
    Antoñanzas F; Gómez P
    Pharmacoeconomics; 2010; 28(11):977-80. PubMed ID: 20936881
    [No Abstract]   [Full Text] [Related]  

  • 15. A tough market.
    Ridley-Smith RM
    N Z Med J; 2007 Aug; 120(1260):U2699. PubMed ID: 17726506
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceutical industry financial performance.
    Goodman M
    Nat Rev Drug Discov; 2009 Dec; 8(12):927-8. PubMed ID: 19949398
    [No Abstract]   [Full Text] [Related]  

  • 17. The European value-pricing game.
    McGuire A
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):5-6. PubMed ID: 22280188
    [No Abstract]   [Full Text] [Related]  

  • 18. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.
    Danzon PM; Ketcham JD
    Front Health Policy Res; 2004; 7():1-54. PubMed ID: 15612334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patent office backlog adds billions to national drug expenditure.
    Gaudry KS; Cummings DE
    Nat Biotechnol; 2014 May; 32(5):436-9. PubMed ID: 24811513
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug industry is considering more use of differential pricing, conference hears.
    Sukkar E
    BMJ; 2011 Dec; 343():d8049. PubMed ID: 22155726
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.